NCAM1 and neoplasm: Taken together, using the property that MCM10 might increase the proportions of Th2 cells and decrease the proportions of NK CD56 bright and pDC cells, it could be attempted to combine MCM10 inhibitors with immune checkpoint inhibitors in the future to reprogram the tumour immune environment and further enhance the effects of immunotherapy for UCEC patients.